Difelikefalin (CR-845; FE-202845) TFA is a synthetic peptide and the first-in-class, peripherally-restricted, selective agonist of the κ-opioid receptor (KOR) for studies related to pruritus.
Bozitinib (PLB-1001; CBT-101) is a highly selective, blood-brain barrier permeable c-MET kinase inhibitor.
Bozitinib (PLB-1001; CBT-101) is a highly selective, blood-brain barrier permeable c-MET kinase inhibitor.
PT2399 is a potent and orally available antagonist of HIF-2 with an IC50 of 6 nM, PT2399 selectively disrupts the heterodimerization of HIF-2α with HIF-1β.
Remibrutinib (LOU064) is a potentially best-in-class "best-in-class" orally active bruton tyrosine kinase (BTK) inhibitor with an IC50 value of 1 nM and an IC50 value of 0.23 μM for inhibition of BTK activity in blood. Remibrutinib can be used to study chronic urticaria (CU).
SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC50=106-175 nM) and directly and independently blocks nucleotide association.
PF-543 hydrochloride is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC50 of 2 nM and a Ki of 3.6 nM. PF-543 hydrochloride is >100-fold selectivity for SPHK1 over SPHK2.
TAK-659 hydrochloride is a highly selective, reversible, orally potent dual inhibitor of SYK/FLT3 that acts on SYK and FLT3 IC50 The values are 3.2 nM and 4.6 nM, respectively. TAK-659 hydrochloride induces tumor cell death without acting on non-tumor cells, with potential to study chronic lymphocytic leukemia (CLL).
TAK-659 hydrochloride is a highly selective, reversible, orally potent dual inhibitor of SYK/FLT3 that acts on SYK and FLT3 IC50 The values are 3.2 nM and 4.6 nM, respectively. TAK-659 hydrochloride induces tumor cell death without acting on non-tumor cells, with potential to study chronic lymphocytic leukemia (CLL).